Citizens Maintains Market Outperform on MBX Biosciences, Raises Price Target to $86

MBX Biosciences, Inc.

MBX Biosciences, Inc.

MBX

0.00

Citizens analyst Jonathan Wolleben maintains MBX Biosciences (NASDAQ: MBX) with a Market Outperform and raises the price target from $76 to $86.